ISDA

Entry Detail

PDB ID:

5MW2

Keywords:

TRANSCRIPTION

Title:

CRYSTAL STRUCTURE OF BCL-6 BTB-domain with BI-3802

Biological Source:

Source Organism:

Homo sapiens

PDB Version:

Deposition Date:

2017-01-18

Release Date:

2017-10-04

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.35 Å

R-Value Free:

0.28

R-Value Work:

0.24

R-Value Observed:

0.24

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:B-cell lymphoma 6 protein
Chain IDs:A
Chain Length:126
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P41182 Pfam ID:PF00651

Ligand Molecules

U52

Primary Citation

Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.

Kerres, N, Steurer, S, Schlager, S, Bader, G, Berger, H, Caligiuri, M, Dank, C, Engen, J.R, Ettmayer, P, Fischerauer, B, Flotzinger, G, Gerlach, D, Gerstberger, T, Gmaschitz, T, Greb, P, Han, B, Heyes, E, Iacob, R.E, Kessler, D, Kolle, H, Lamarre, L, Lancia, D.R, Lucas, S, Mayer, M, Mayr, K, Mischerikow, N, Muck, K, Peinsipp, C, Petermann, O, Reiser, U, Rudolph, D, Rumpel, K, Salomon, C, Scharn, D, Schnitzer, R, Schrenk, A, Schweifer, N, Thompson, D, Traxler, E, Varecka, R, Voss, T, Weiss-Puxbaum, A, Winkler, S, Zheng, X, Zoephel, A, Kraut, N, McConnell, D, Pearson, M, Koegl, M.Show

Cell Rep 20 2860 2875 (2017)

PMID: 28930682 DOI: 10.1016/j.celrep.2017.08.081

Abstact

The transcription factor BCL6 is a known driver of oncogenesis in lymphoid malignancies, including diffuse large B cell lymphoma (DLBCL). Disruption of its interaction with transcriptional repressors interferes with the oncogenic effects of BCL6. We used a structure-based drug design to develop highly potent compounds that block this interaction. A subset of these inhibitors also causes rapid ubiquitylation and degradation of BCL6 in cells. These compounds display significantly stronger induction of expression of BCL6-repressed genes and anti-proliferative effects than compounds that merely inhibit co-repressor interactions. This work establishes the BTB domain as a highly druggable structure, paving the way for the use of other members of this protein family as drug targets. The magnitude of effects elicited by this class of BCL6-degrading compounds exceeds that of our equipotent non-degrading inhibitors, suggesting opportunities for the development of BCL6-based lymphoma therapeutics.

Legend

Protein

Chemical

Disease

Primary Citation of related structures